SpringerLink
Log in

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

  • Letter to the Editor
  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sutton SS, Magagnoli J, Cummings TH, Dettling T, Lovelace B, Christoph MJ et al (2023) Real-world clinical outcomes among US veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis 56(1):137–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang SV, Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM et al (2023) Emulation of Randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329(16):1376–1385

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JPA (2016) Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: Meta-epidemiological survey. BMJ (Online). ;352

  4. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H et al (2012) Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 33:1893–1901

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ren J, Cislo P, Cappelleri JC, Hlavacek P, DiBonaventura M (2023) Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study. BMC Med Res Methodol. 23(1)

  6. Cohen AT, Lewis M, Connor A, Connolly SJ, Yue P, Curnutte J et al (2022) Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding. J Am Coll Emerg Physicians Open 3(2):1–10

    Google Scholar 

  7. Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B et al (2022) Andexanfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 26(1)

  8. Keinath JJ, Lekura J, Hauser CD, Bajwa MK, Bloome ME, Kalus JS et al (2023) Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor xa inhibitor associated bleeds. J Thromb Thrombolysis.

Download references

Acknowledgements

The NIHR Biomedical Research Centre (NIHR203326) and the British Heart Foundation Accelerator (BHF) (AA/18/2/34218) have supported the Institute of Cardiovascular Sciences where this research is based. The opinions expressed in this paper are those of the authors and do not represent any of the listed organisations. RJB is supported through a BHF Dedicated Scholarship.

Funding

Dr. Richard John Buka MBChB (Hons). British Heart Foundation, http://dx.doi.org/10.13039/501100000274.

Author information

Authors and Affiliations

  1. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

    Richard J Buka & Phillip LR Nicolson

  2. Staffordshire Thrombosis and Anticoagulation Service, University Hospitals North Midlands NHS Trust, Stoke-on-Trent, UK

    David J Sutton

  3. Department of Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

    Phillip LR Nicolson

Authors
  1. Richard J Buka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phillip LR Nicolson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J Buka.

Ethics declarations

Ethical approval

No ethical approval was required or sought.

Financial disclosures

RJB has received honoraria from Bayer, Sobi, and Sanofi, and Takeda.

DJS has received honoraria from Pfizer-BMS and Bayer.

PLRN has received research grants from Novartis, Principia, Sanofi, and Rigel Pharmaceuticals and has received had honoraria from Bayer, Grifols and Takeda.

RJB and PLRN have received an externally-sponsored research grant from AstraZeneca to audit the use of reversal agents for direct oral anticoagulant-associated bleeding across the UK.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buka, R.J., Sutton, D.J. & Nicolson, P.L. Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis 57, 739–741 (2024). https://doi.org/10.1007/s11239-024-02948-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-024-02948-5

Search

Navigation